Morbidity results from the NSABP B‐32 trial comparing sentinel lymph node dissection versus axillary dissection
Top Cited Papers
Open Access
- 14 July 2010
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 102 (2), 111-118
- https://doi.org/10.1002/jso.21535
Abstract
Background and Objectives Three year post‐surgical morbidity levels were compared between patients with negative sentinel lymph node dissection alone (SLND) and those with negative sentinel node dissection and negative axillary lymph node dissection (ALND) in the NSABP B‐32 trial. Methods A total of 1,975 ALND and 2,008 SLND node negative breast cancer patients had shoulder range of motion and arm volumes assessed along with self reports of arm tingling and numbness. Relative shoulder abduction deficits and relative arm volume differences between ipsilateral and contralateral arms were calculated. Results Shoulder abduction deficits ≥10% peaked at 1 week for the ALND (75%) and SLND (41%) groups. Arm volume differences ≥10% at 36 months were evident for the ALND (14%) and SLND (8%) groups. Numbness and tingling peaked at 6 months for the ALND (49%, 23%) and SLND (15%, 10%) groups. Logistic regression correlates of residual morbidity included treatment group, age, handedness, tumor size, systemic chemotherapy, and radiation to the axilla. Conclusions Although residual morbidity for both treatment groups was evident, the results of the NSABP B‐32 study indicate the superiority of the SLND compared to the ALND treatment approach relative to post‐surgical morbidity outcomes over a 3‐year follow‐up period. J. Surg. Oncol. 2010;102:111–118.Keywords
Funding Information
- National Cancer Institute, Department of Health and Human Services, Public Health Service (P30 CA022435, 5RO1CA74137-9, U10-CA-12027, U10-CA-69651, U10-CA-37377, U10-CA-69974)
This publication has 10 references indexed in Scilit:
- The Risk of Developing Arm Lymphedema Among Breast Cancer Survivors: A Meta-Analysis of Treatment FactorsAnnals of Surgical Oncology, 2009
- Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? One-Year Outcomes of Sentinel Node Biopsy Versus Axillary Clearance (SNAC): A Randomized Controlled Surgical TrialAnnals of Surgical Oncology, 2008
- Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: Results of the sentinella–GIVOM Italian randomised clinical trialEuropean Journal of Surgical Oncology, 2008
- Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trialThe Lancet Oncology, 2007
- Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC TrialJNCI Journal of the National Cancer Institute, 2006
- Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancerBreast Cancer Research and Treatment, 2005
- Morbidity After Sentinel Lymph Node Biopsy in Primary Breast Cancer: Results From a Randomized Controlled TrialJournal of Clinical Oncology, 2005
- NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial.Annals of Surgical Oncology, 2004
- NSABP-32: Phase III, Randomized Trial Comparing Axillary Resection with Sentinal Lymph Node Dissection: A Description of the TrialAnnals of Surgical Oncology, 2004
- A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast CancerThe New England Journal of Medicine, 2003